PepGen Inc. Files 8-K Report
Ticker: PEPG · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1835597
| Field | Detail |
|---|---|
| Company | Pepgen Inc. (PEPG) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
PepGen filed an 8-K, mostly financial exhibits. Nothing major to see here yet.
AI Summary
On March 13, 2024, PepGen Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no other specific events detailed in the provided excerpt. The company is incorporated in Delaware and headquartered in Boston, Massachusetts.
Why It Matters
This filing indicates routine corporate reporting, likely containing financial updates or exhibit submissions that are important for investors to track the company's financial health and disclosures.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate material events or risks.
Key Numbers
- 001-41374 — Commission File Number (Identifies the company's filing with the SEC.)
- 85-3819886 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PepGen Inc. (company) — Registrant
- March 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Boston, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for PepGen Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 13, 2024.
In which state is PepGen Inc. incorporated?
PepGen Inc. is incorporated in Delaware.
What is the address of PepGen Inc.'s principal executive offices?
PepGen Inc.'s principal executive offices are located at 321 Harrison Avenue, 8th Floor, Boston, Massachusetts 02118.
Does this filing report any 'Other Events' for PepGen Inc.?
The filing lists 'Other Events' as an item information category, but the provided excerpt does not detail any specific events under this category.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-03-13 07:20:59
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share PEPG Nasdaq Global Select
Filing Documents
- pepg-20240313.htm (8-K) — 37KB
- pepg-ex99_1.htm (EX-99.1) — 22KB
- img148377401_0.jpg (GRAPHIC) — 9KB
- 0000950170-24-030505.txt ( ) — 190KB
- pepg-20240313.xsd (EX-101.SCH) — 25KB
- pepg-20240313_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On March 13, 2024, PepGen Inc. (the "Company") announced that it received U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51. A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Description 99.1 Press release issued by PepGen Inc. on March 13, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PEPGEN INC. Date: March 13, 2024 By: /s/ Noel Donnelly Noel Donnelly, Chief Financial Officer